Canakinumab for the Treatment of Postprandial Hypoglycemia

Inclusion Criteria: * Patients after bariatric surgery (i.e. sleeve gastrectomy, Roux-en-Y gastric bypass, omega-loop bypass, biliopancreatic diversion) with documented hypoglycemia, i. e. \< 3.0 mmol/l and at least 5 hypoglycemic episodes per week despite dietary modification * For women with child-bearing potential, willingness to use contraceptive measures adequate to prevent pregnancy during the study * Informed Consent as documented by signature Exclusion Criteria: * Any type of diabetes mellitus according to ADA criteria * Intolerance to the study drug * Signs of current infection * Any use of immunosuppressive medication * Use of any drug therapy for postbariatric hypoglycemia apart from acarbose (all remaining drugs have to be discontinued four half-life times before screening phase) * Neutropenia (leukocyte count \< 1.5 × 109/L or ANC \< 0.5 × 109/L) * Anemia (hemoglobin \< 11 g/dL for males, \< 10 g/dL for females) * Clinically significant kidney or liver disease (creatinine \> 1.5 mg/dL, AST/ALT \> 2 × ULN, alkaline phosphatase \> 2 × ULN, or total bilirubin \[tBili\] \> 1.5 × ULN) * Uncontrolled congestive heart failure * Uncontrolled malignant disease * Currently pregnant or breastfeeding * Known or suspected non-compliance, drug or alcohol abuse * Meeting the criteria for vulnerability (e.g. participants incapable of judgment or participants under tutelage) * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. * Participation in another clinical trial using investigational drugs in the last 30 days or planned participation in the next 60 days * Previous enrolment into the current study, * Enrolment of the investigator, his/her family members, employees and other dependent persons